Henry Yu
Physician Assistant · Bronx, NYNPI 1629043096
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $635,752 of the $1,002,269 with a category attached, or 63.4%. 31 manufacturers reported payments, led by UCB, Inc. at 25.8% of the total. 2025 is the largest year on record at $307,092, 6.6 times the $46,670 reported in 2021. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,666 payments — averaging $375.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$258K
- LEO Pharma Inc.$143K
- Pfizer$111K
- Johnson & Johnson$91K
- AbbVie$73K
- Galderma Laboratories, L.p.$72K
- plus $253K from 25 others
What the payments were for
- Consulting fees$178,99918%
- Speaking & faculty fees$635,75263%
- Travel & lodging$134,04413%
- Food & beverage$53,1325%
- Education$3420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 521 | $258,368 |
| LEO Pharma Inc. | 337 | $143,014 |
| Pfizer | 164 | $111,402 |
| Johnson & Johnson | 223 | $90,921 |
| AbbVie | 263 | $73,156 |
| Galderma Laboratories, L.p. | 214 | $72,001 |
| Dermavant Sciences, Inc. | 160 | $67,533 |
| Arcutis Biotherapeutics, Inc. | 206 | $54,018 |
| Sun Pharmaceutical Industries Inc. | 109 | $25,004 |
| Boehringer Ingelheim | 29 | $23,782 |
| E.r. Squibb & Sons, L.L.C. | 71 | $18,796 |
| Incyte Corporation | 78 | $16,456 |
| Botanix SB Inc | 26 | $10,195 |
| Janssen Scientific Affairs, LLC | 19 | $9,859 |
| Organon | 21 | $9,533 |
| Amgen | 27 | $6,261 |
| EPI Health, LLC | 32 | $3,797 |
| Novartis | 34 | $1,746 |
| Regeneron Healthcare Solutions, Inc. | 28 | $1,672 |
| Mayne Pharma Commercial LLC | 1 | $1,100 |
| Sanofi US Services Inc. | 1 | $1,061 |
| Sanofi | 29 | $982 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 49 | $702 |
| Kowa Pharmaceuticals America, Inc. | 1 | $400 |
| Almirall LLC | 12 | $185 |
| AstraZeneca | 1 | $127 |
| Lilly USA, LLC | 4 | $87 |
| Helsinn Therapeutics (U.S.), Inc. | 3 | $60 |
| Biofrontera Inc. | 1 | $18 |
| Sandoz | 1 | $17 |
| Dermira, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,002,269 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BimzelxBimekizumab-Bkzx | 42 | $583,453 |
| Dupixent SyringeDupilumab | 147 | $550,904 |
| IlumyaTildrakizumab-Asmn | 26 | $439,241 |
| TremfyaGuselkumab | 32 | $427,949 |
| OpzeluraRuxolitinib Phosphate | 198 | $413,164 |
| SkyriziRisankizumab-Rzaa | 19 | $396,727 |
| AdbryTralokinumab-Ldrm | 109 | $374,231 |
| RinvoqUpadacitinib | 50 | $328,050 |
| VtamaTapinarof | 194 | $274,606 |
| ZoryveRoflumilast | 264 | $230,106 |
| CibinqoAbrocitinib | 32 | $186,794 |
| Cimzia (2 Pack)Certolizumab Pegol | 20 | $113,170 |
| NemluvioNemolizumab-Ilto | 15 | $93,027 |
| JubliaEfinaconazole | 95 | $71,644 |
| Adbry AutoinjectorTralokinumab-Ldrm | 20 | $67,631 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSkyrizi, Rinvoq | $73,156 | $724,77769 claims |
| UCB, Inc.Bimzelx, Cimzia (2 Pack) | $258,368 | $696,62462 claims |
| Sun Pharmaceutical Industries Inc.Ilumya | $25,004 | $439,24126 claims |
| Johnson & JohnsonTremfya | $90,921 | $427,94932 claims |
| Incyte CorporationOpzelura | $16,456 | $413,164198 claims |
| LEO Pharma Inc.Adbry | $143,014 | $374,231109 claims |
| Dermavant Sciences, Inc.Vtama | $67,533 | $274,606194 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $54,018 | $230,106264 claims |
| PfizerCibinqo | $111,402 | $186,79432 claims |
| Galderma Laboratories, L.p.Nemluvio, Oracea, Epsolay, Soolantra | $72,001 | $151,488100 claims |
| Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia, Duobrii | $702 | $92,905116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in Bronx
- Julius NwosuBronx$256K
- George LopezBronx$46K
- Kimberley RubinoBronx$29K
- Michael AsbachAmherst$962K
- Janelle BunceJamestown$565K
- Kristyl Cuenca-SiskoNew York$478K
- Melissa WhiteGarden City$320K
- Lawrence HermanHolbrook$315K
- Kaitlyn NelsonBrooklyn$289K
- Sari KatzGarden City$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.